Visit 2 to visit 6 (day 3 to day 28) of controlled treatment phase
tremor, vision impairments
ADVERSE EVENTS
During the first 4 weeks after randomisation, five study visits are performed and assessments should be conducted according to Fig. At visit 6, the patient should be assessed for signs of de novo occurrence of tremor or vision impairments. If detected, these should be documented as adverse events.